

# Ivo Buchhalter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7546728/publications.pdf>

Version: 2024-02-01

28  
papers

5,780  
citations

304368

22  
h-index

500791

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

10560  
citing authors

#	ARTICLE	IF	CITATIONS
1	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
2	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787
3	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	13.5	702
4	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	13.7	520
5	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	7.7	438
6	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	13.7	318
7	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	5.1	268
8	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. <i>Nature Communications</i> , 2015, 6, 10001.	5.8	266
9	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	3.9	203
10	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	5.1	151
11	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	2.3	131
12	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
13	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	0.8	106
14	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and <i>real-life</i> analysis of three larger gene panels. <i>International Journal of Cancer</i> , 2019, 144, 2303-2312.	2.3	95
15	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	13.7	94
16	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	13.7	94
17	<i>EML4-ALK</i> fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK <sup>+</sup> non-small cell lung cancer. <i>International Journal of Cancer</i> , 2018, 142, 2589-2598.	2.3	93
18	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. <i>International Journal of Cancer</i> , 2019, 145, 649-661.	2.3	85

#	ARTICLE	IF	CITATIONS
19	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
20	Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2017, 214, 2073-2088.	4.2	30
21	Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. <i>Pathology</i> , 2018, 50, 327-332.	0.3	27
22	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158.	3.9	26
23	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. <i>Pathology</i> , 2018, 50, 703-710.	0.3	21
24	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	20
25	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. <i>Acta Neuropathologica</i> , 2018, 135, 635-638.	3.9	17
26	Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. <i>Oncolmmunology</i> , 2016, 5, e1213931.	2.1	14
27	Butler enables rapid cloud-based analysis of thousands of human genomes. <i>Nature Biotechnology</i> , 2020, 38, 288-292.	9.4	11
28	Framework for quality assessment of whole genome cancer sequences. <i>Nature Communications</i> , 2020, 11, 5040.	5.8	5